By mandating hydration breaks at this year’s World Cup, FIFA is facilitating a change with huge financial implications as airing more ads boosts broadcasting revenue.

A new antibody‑drug conjugate nearly doubles survival and extends overall survival in advanced triple‑negative breast cancer, offering a more precise first‑line.

The death rate in the group treated with daraxonrasib was 60% lower than those on chemotherapy. This is hailed as a major advance against metastatic pancreatic cancer.

Forecasts remain central to healthcare policy evaluation. And so, their accuracy is particularly important in relation to possible expansion of GLP-1 coverage.

Engineered fluorescent nanobodies that work inside living cells can label multiple proteins in different colors at once, revealing real-time cellular activity.

Upheaval at the U.S. Preventive Services Task Force may reshape coverage of preventive care by insurance, possibly leading to removal of previously covered items.

While the most favored nation initiatives have bold aims to lower the cost of drugs, the impact is limited, and in some instances unclear, a case of style over substance.

A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent chemotherapy directly into cancer cells.

While PBM reforms that passed earlier this year will spur further changes in the way business is conducted, it’s anti-trust legislation that could have the most impact.

Inclusion of weight loss drugs on insurer formularies is a meaningful step towards expanding access. But having a product listed doesn’t necessarily mean it’s covered.